Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.
Adaptive Biotechnologies insider filing reports sales. The Form 144 lists 122,523 Restricted Stock Units to be sold with an effective date of 03/10/2026. The filing also details multiple sales by Julie Rubinstein between 03/03/2026 and 03/13/2026, showing individual trade sizes and proceeds.
ADPT filed a Rule 144 notice describing proposed sales of equity awards dated 03/10/2026. The filing lists 140,666 Restricted Stock Units and 329,600 Performance Stock Units to be sold by the issuer through Morgan Stanley Smith Barney LLC.
The filing also reports recent open-market sales by Harlan Robins during Jan–Mar 2026, including multiple transactions such as 14,233 and 10,000 shares on March and January dates.
Chad Robins filed a Form 144 notifying proposed sales of Common Stock in multiple transactions. The notice lists several sales on dates in January–March 2026, including a 03/03/2026 entry for 53,083 shares and multiple entries on 03/02/2026 and 02/27/2026.
The filing lists Restricted Stock Units (140,567) and Performance Stock Units (329,600) with an 03/10/2026 date. The Form 144 records individual share sales with dollar amounts per transaction; cash‑flow treatment and any aggregate total are not provided in the excerpt.
Adaptive Biotechnologies President and COO Julie Rubinstein reported a series of option exercises and stock sales. She exercised options to acquire 44,166 shares of common stock at an exercise price of $6.55 per share and sold 179,703 shares in multiple open-market transactions, including sales at $12.63, $12.96, $13.17, $13.43 and $14.08 per share. A portion of the shares sold was mandated to cover tax withholding on RSU vesting, and all transactions were carried out under a Rule 10b5-1 trading plan. After these transactions, she directly holds 507,934 shares of common stock and retains 62,827 fully vested stock options exercisable at $6.55 per share expiring on February 7, 2028.
Adaptive Biotechnologies Corp director Michelle Renee Griffin reported an open-market sale of 15,394 shares of Common Stock at a weighted-average price of $13.91 per share. The shares were sold in multiple trades between $13.84 and $13.96. After this sale, she directly holds 15,625 shares, meaning her personal stake was significantly reduced but she continues to own stock in the company.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an open-market sale of 30,593 shares of common stock at a weighted average price of $14.08 per share on March 11, 2026. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance. Following the sale, Lo directly holds 291,374 shares of Adaptive Biotechnologies common stock and has an additional 2,500 shares held indirectly through a spouse. The sale price range for the trades was between $13.81 and $14.38 per share.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky sold 41,338 shares of common stock on March 11, 2026 at an average price of $13.17 per share. According to the disclosure, this transaction was required to cover tax withholding obligations related to vesting restricted stock units and was executed under a mandatory “sell to cover” election, meaning it was not a discretionary trade. Following the sale, Bobulsky directly holds 427,775 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benz eno, reported an open-market sale of 63,103 shares of common stock at $13.17 per share. After the transaction, she directly holds 272,751 shares.
The company’s equity plan required this sale to cover tax withholding on vested restricted stock units, so it was a mandated “sell-to-cover” transaction rather than a discretionary trade.
Adaptive Biotechnologies Corp Chief Financial Officer Kyle Piskel reported a mandated sale of 18,672 shares of Common Stock on March 11, 2026. The shares were sold at an average price of $13.17 per share and were executed as an open-market transaction.
According to the disclosure, this sale was required to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans. The footnote states the transaction was a “sell to cover” and not a discretionary trade by Piskel. After the sale, he directly holds 259,840 shares of Adaptive Biotechnologies Corp common stock.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported selling a total of 470,266 shares of common stock on March 11, 2026 at $13.17 per share. According to the footnotes, both sales were mandated "sell to cover" transactions to satisfy tax withholding on vesting RSUs and performance share units, and did not represent discretionary trading decisions. After these transactions, Robins directly owned 1,522,058 shares of Adaptive Biotechnologies common stock.